Department of Dermatology and Venereology, Medical University of Białystok, Białystok, Poland.
Department of Urology and Urological Oncology, Municipal Polyclinical Hospital, Olsztyn, Poland.
Front Public Health. 2024 Apr 17;12:1339196. doi: 10.3389/fpubh.2024.1339196. eCollection 2024.
Psoriasis is one the most common skin diseases associated with a great decrease in the quality of patients' lives.
We aimed to study sexual dysfunctions in psoriatic patients using the Female Sexual Function Index (FSFI) for women and the International Index of Erectile Function (IIEF) for men via an anonymous online survey. The study included 80 psoriatic patients and 75 controls without dermatoses.
There was a downward trend in the total IIEF score in psoriatic men compared to controls. 58% of male patients and 76% of controls had a normal IIEF score. There was no significant difference in IIEF between patients treated and not with systemic agents. 62% of female patients had a decreased FSFI score, whereas in the control group, the majority of subjects (54%) had a normal FSFI score. There was no significant difference in FSFI score between patients and controls. Female patients treated with systemic antipsoriatic agents had significantly worse lubrication, satisfaction with sexual life, and pain.
Our study has shown that the majority of questioned female psoriatic patients had sexual dysfunction according to FSFI, particularly they had worse satisfaction with sexual life and less sexual desire compared to women without psoriasis. The majority of male patients did not have sexual dysfunction according to IIEF, however, they had significantly worse overall satisfaction with sexual life and confidence to keep an erection. Systemic antipsoriatic treatment does not probably influence sexual dysfunctions in men but it does in women although we were not able to assess the severity or resolution of lesions after those treatments. However embarrassing, psoriatic patients should be questioned about their sexual lives by dermatologists, and more studies are needed to explore this matter.
银屑病是一种常见的皮肤病,会极大地降低患者的生活质量。
我们旨在通过匿名在线调查,使用女性性功能指数(FSFI)和男性国际勃起功能指数(IIEF),研究银屑病患者的性功能障碍。研究纳入了 80 例银屑病患者和 75 例无皮肤病的对照者。
与对照组相比,银屑病男性的总 IIEF 评分呈下降趋势。58%的男性患者和 76%的对照组的 IIEF 评分正常。接受和未接受系统治疗的患者之间 IIEF 无显著差异。62%的女性患者 FSFI 评分降低,而对照组中大多数患者(54%)FSFI 评分正常。患者和对照组之间 FSFI 评分无显著差异。接受系统抗银屑病药物治疗的女性患者在润滑、性生活满意度和疼痛方面明显更差。
我们的研究表明,大多数被调查的女性银屑病患者根据 FSFI 存在性功能障碍,尤其是与无银屑病的女性相比,她们的性生活满意度和性欲明显更差。大多数男性患者根据 IIEF 没有性功能障碍,但他们的整体性生活满意度和保持勃起的信心明显更差。系统抗银屑病治疗可能不会影响男性的性功能障碍,但会影响女性,尽管我们无法评估这些治疗后皮损的严重程度或缓解情况。尽管尴尬,但皮肤科医生应询问银屑病患者的性生活情况,需要进一步研究来探讨这个问题。